tiprankstipranks
Trending News
More News >
Integrum AB Class B (SE:INTEG.B)
:INTEG.B
Advertisement

Integrum AB Class B (INTEG.B) AI Stock Analysis

Compare
0 Followers

Top Page

SE:INTEG.B

Integrum AB Class B

(Frankfurt:INTEG.B)

Rating:62Neutral
Price Target:
kr44.00
▲(4.76%Upside)
The stock score is primarily driven by strong technical analysis, indicating bullish market momentum. However, financial performance challenges and poor valuation metrics weigh heavily on the overall score. The absence of earnings call insights or notable corporate events maintains focus on existing financial and technical data.

Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)

Integrum AB Class B Business Overview & Revenue Model

Company DescriptionIntegrum AB Class B (INTEG.B) is a Swedish medical technology company specializing in the development of innovative systems for bone-anchored prosthetics. The company operates within the healthcare and medical device sectors, focusing on improving the quality of life for amputees. Integrum's core product, the OPRA Implant System, is a proprietary solution that offers a unique method of attaching prosthetic limbs directly to the bone, providing improved functionality and comfort compared to traditional socket prosthetics.
How the Company Makes MoneyIntegrum AB generates revenue primarily through the sale of its OPRA Implant System to healthcare providers and clinics around the world. The company earns money by manufacturing and distributing these advanced prosthetic solutions, which are typically covered by insurance providers or paid for by healthcare institutions. Additionally, Integrum may engage in strategic partnerships with medical device companies or healthcare organizations to expand the adoption of its technology. The company's earnings are also bolstered by ongoing research and development efforts, which may lead to new product offerings or enhancements to existing systems, thus attracting more customers.

Integrum AB Class B Financial Statement Overview

Summary
Integrum AB is facing financial difficulties, with declining revenues and increasing losses. Despite a strong equity position, profitability and cash flow generation are major concerns. Operational challenges are evident, but the stable balance sheet provides some support.
Income Statement
45
Neutral
Integrum AB's income statement shows a declining trend in revenue with a significant drop from 2024 to 2025. The gross profit margin remains relatively high, indicating efficient cost management in production. However, the company has faced increasing operating losses, as seen in the negative EBIT and EBITDA margins, signaling challenges in covering operational expenses. Net profit margins have also deteriorated, reflecting overall financial struggles in maintaining profitability.
Balance Sheet
70
Positive
The balance sheet demonstrates a strong equity position with a high equity ratio, indicating financial stability and a lower reliance on debt. The debt-to-equity ratio is low, which is favorable and shows prudent financial management. Return on equity, however, is negative, reflecting the company's inability to generate profit from its equity base. Overall, the balance sheet is stable with potential for leveraging equity for growth.
Cash Flow
50
Neutral
Cash flow analysis reveals consistent challenges in generating positive operating cash flow, contributing to negative free cash flow. The operating cash flow to net income ratio indicates difficulties in converting income to cash. Financing activities have been a source of cash, but reliance on external financing could pose risks if not managed carefully. There is a negative trend in free cash flow growth, pointing to potential liquidity concerns.
BreakdownJun 2025Jun 2024Jun 2023Jun 2022Jun 2021
Income Statement
Total Revenue91.10M104.12M74.27M55.72M43.09M
Gross Profit75.38M91.26M60.84M46.56M34.89M
EBITDA-35.50M8.76M-20.24M2.60M-1.59M
Net Income-30.85M4.03M-16.18M21.27M-2.14M
Balance Sheet
Total Assets203.25M164.86M165.17M180.44M37.21M
Cash, Cash Equivalents and Short-Term Investments39.60M16.90M41.92M75.34M7.66M
Total Debt4.84M6.42M7.92M580.89K485.92K
Total Liabilities25.38M22.07M21.64M20.70M12.91M
Stockholders Equity177.88M142.79M143.53M159.74M24.29M
Cash Flow
Free Cash Flow-50.59M-24.37M-36.50M-49.55M-7.47M
Operating Cash Flow-37.70M-12.74M-25.10M-20.28M-5.76M
Investing Cash Flow-12.89M-11.63M-11.40M-29.27M-1.71M
Financing Cash Flow73.29M-648.54K3.08M117.23M2.06M

Integrum AB Class B Technical Analysis

Technical Analysis Sentiment
Positive
Last Price42.00
Price Trends
50DMA
22.67
Positive
100DMA
18.96
Positive
200DMA
19.58
Positive
Market Momentum
MACD
6.05
Negative
RSI
89.29
Negative
STOCH
97.03
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 42 is above the 20-day moving average (MA) of 27.44, above the 50-day MA of 22.67, and above the 200-day MA of 19.58, indicating a bullish trend. The MACD of 6.05 indicates Negative momentum. The RSI at 89.29 is Negative, neither overbought nor oversold. The STOCH value of 97.03 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.

Integrum AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
kr888.57M-19.17%-12.50%-783.92%
52
Neutral
kr5.49B9.89-63.86%2.02%27.11%26.73%
50
Neutral
€393.77M-33.54%72.05%33.68%
49
Neutral
kr613.84M-51.41%3.57%-925.35%
46
Neutral
kr455.81M-88.97%-0.61%54.19%
46
Neutral
kr356.69M-45.57%-6.82%-449.87%
40
Neutral
€342.07M-190.21%16.98%36.29%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:INTEG.B
Integrum AB Class B
41.70
-8.70
-17.26%
SE:ACARIX
Acarix AB
0.43
-0.06
-12.65%
SE:DOXA
Doxa AB
0.48
-0.62
-56.64%
SE:MNTC
Mentice AB
13.95
-19.17
-57.88%
SE:QLINEA
Q-linea AB
56.00
-434.97
-88.59%
SE:BRAIN
BrainCool AB
1.51
-0.70
-31.61%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 23, 2025